LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Exact Sciences Corp

Fermé

SecteurSoins de santé

101.29 -0.12

Résumé

Variation du prix de l'action

24h

Actuel

Min

101.07

Max

101.48

Chiffres clés

By Trading Economics

Revenu

-18M

-20M

Ventes

40M

851M

BPA

0.24

Marge bénéficiaire

-2.303

Employés

6,900

EBITDA

-27M

38M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-5.31% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.5B

19B

Ouverture précédente

101.41

Clôture précédente

101.29

Sentiment de l'Actualité

By Acuity

100%

0%

360 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Exact Sciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 nov. 2025, 13:14 UTC

Acquisitions, Fusions, Rachats

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20 nov. 2025, 13:11 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- Update

20 nov. 2025, 12:55 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion

20 nov. 2025, 16:51 UTC

Acquisitions, Fusions, Rachats

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20 nov. 2025, 15:08 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20 nov. 2025, 14:39 UTC

Market Talk
Acquisitions, Fusions, Rachats

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20 nov. 2025, 14:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20 nov. 2025, 13:51 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20 nov. 2025, 13:25 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20 nov. 2025, 13:24 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:59 UTC

Acquisitions, Fusions, Rachats

Correction to Abbott to Acquire Exact Sciences for $21B Article

20 nov. 2025, 12:58 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:56 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21B -- Update

20 nov. 2025, 12:54 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Expect to Maintain Investment-Grade Credit Rating >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs to Fund Exact Sciences Deal With Cash on Hand, Debt Financing >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Exact Sciences Deal Adding to Adjusted EPS in 2028, Beyond >ABT EXAS

20 nov. 2025, 12:53 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Exact Sciences Deal Cutting Adjusted EPS by 20c in 2026, 16c in 2027 >ABT EXAS

20 nov. 2025, 12:52 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees at Least $100 Million Annual Pretax Synergies From Exact Sciences Deal by 2028 >ABT EXAS

20 nov. 2025, 12:46 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

20 nov. 2025, 12:40 UTC

Acquisitions, Fusions, Rachats

Abbott to Acquire Exact Sciences for $21B

20 nov. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Exact Sciences Deal Has Enterprise Value of About $23 Billion >ABT EXAS

20 nov. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Exact Sciences to Be Acquired for $105/Share; Closed Wednesday at $86.18 >ABT EXAS

20 nov. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Abbott Labs Sees Acquisition Immediately Adding to Revenue Growth, Gross Margin >ABT EXAS

20 nov. 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

Abbott Labs: Exact Sciences Deal Has Total Equity Value of About $21 Billion >ABT EXAS

20 nov. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Abbott to Buy Exact Sciences for $105/Share >ABT EXAS

20 nov. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Abbott To Acquire Exact Sciences, A Leader In Large And Fast-growing Cancer Screening And Precision Oncology Diagnostics Segments >ABT

19 nov. 2025, 21:27 UTC

Acquisitions, Fusions, Rachats

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

Comparaison

Variation de prix

Exact Sciences Corp prévision

Objectif de Prix

By TipRanks

-5.31% baisse

Prévisions sur 12 Mois

Moyen 96.06 USD  -5.31%

Haut 105 USD

Bas 50 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

21 ratings

3

Achat

18

Maintien

0

Vente

Score Technique

By Trading Central

45.6 / 54.37Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

360 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
help-icon Live chat